Accuray Inc (ARAY)

5.20
0.15 2.97
NASDAQ : Health Care
Prev Close 5.05
Open 5.05
Day Low/High 5.00 / 5.25
52 Wk Low/High 4.75 / 7.54
Volume 398.28K
Avg Volume 607.90K
Exchange NASDAQ
Shares Outstanding 81.69M
Market Cap 412.55M
EPS -0.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Commit To Buy Accuray At $4, Earn 11.6% Annualized Using Options

Commit To Buy Accuray At $4, Earn 11.6% Annualized Using Options

Investors eyeing a purchase of Accuray Inc shares, but cautious about paying the going market price of $5.08/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the June 2017 put at the $4 strike, which has a bid at the time of this writing of 25 cents.

Prospective, Multi-Institutional Study Shows Five Treatments With The CyberKnife® System Provide Excellent Disease Control For Prostate Cancer Patients

Prospective, Multi-Institutional Study Shows Five Treatments With The CyberKnife® System Provide Excellent Disease Control For Prostate Cancer Patients

ASTRO Selects the Data for Center Stage at Largest Annual Meeting of Radiation Oncologists

Accuray To Unveil New Technology At The ASTRO 2016 Annual Meeting

Accuray To Unveil New Technology At The ASTRO 2016 Annual Meeting

Innovations in Hardware and Software Solutions and New Clinical Data Reinforce the Benefits of Accuray Systems in Treating a Wide Range of Cancer Cases

Accuray (ARAY) Stock Sharply Lower After Q4 Results, Guidance

Accuray (ARAY) Stock Sharply Lower After Q4 Results, Guidance

Accuray (ARAY) reported a larger-than-anticipated loss for the 2016 fiscal fourth quarter and a downbeat forecast following Wednesday's closing bell.

Will Accuray (ARAY) Stock Fall on Q4 Miss, Downbeat Outlook?

Will Accuray (ARAY) Stock Fall on Q4 Miss, Downbeat Outlook?

Accuray (ARAY) posted a wider-than-expected loss for the 2016 fiscal fourth quarter after Wednesday's market close.

Accuray CE Marks Its New Radixact™ System

Accuray CE Marks Its New Radixact™ System

Next Generation Image-Guided Radiation Therapy Platform and Integrated Software Solutions are Now Available for Use by Clinicians in the European Union

New Data Show InCise™ Multileaf Collimator For The CyberKnife® M6™ System May Expand Patient Population Eligible For Precise Radiation Treatments

New Data Show InCise™ Multileaf Collimator For The CyberKnife® M6™ System May Expand Patient Population Eligible For Precise Radiation Treatments

Clinical Research on the CyberKnife® System, Including the Multileaf Collimator, Presented at Leading Scientific Meeting for Medical Physicists

New Data Demonstrating TomoTherapy® System Adaptive Capabilities And Workhorse Reliability Presented At Leading Scientific Meeting For Medical Physicists

New Data Demonstrating TomoTherapy® System Adaptive Capabilities And Workhorse Reliability Presented At Leading Scientific Meeting For Medical Physicists

Clinical Research Also Showcases Innovative Approaches to Expanding TomoTherapy Platform Functionality

Trade These 5 Biotech Breakouts Now for Big Gains

Trade These 5 Biotech Breakouts Now for Big Gains

Here's a technical look at how to trade five biotech stocks that are setting up to break out and trade much higher.

Accuray Receives 510(k) FDA Clearance For The Radixact™ Image-Guided Radiation Therapy Platform And Integrated Software

Accuray Receives 510(k) FDA Clearance For The Radixact™ Image-Guided Radiation Therapy Platform And Integrated Software

Next Generation "Smart" System Enables Clinicians to Provide Highly Precise Treatment, Efficiently, for More Patients, Every Day

FUCAM Treats 1,000 Breast Cancer Patients With The TomoTherapy® System

FUCAM Treats 1,000 Breast Cancer Patients With The TomoTherapy® System

System Dedicated Solely to Breast Cancer Care Provides Excellent Clinical Outcomes

United Kingdom's NHS Supply Chain To Acquire Seven TomoTherapy® Systems

United Kingdom's NHS Supply Chain To Acquire Seven TomoTherapy® Systems

Largest Ever Accuray Deal Will Provide More Cancer Patients in the United Kingdom (UK) Access to Advanced, Precise Radiation Treatments

Commit To Purchase Accuray At $5, Earn 23.2% Annualized Using Options

Commit To Purchase Accuray At $5, Earn 23.2% Annualized Using Options

Investors considering a purchase of Accuray Inc shares, but tentative about paying the going market price of $5.30/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the September put at the $5 strike, which has a bid at the time of this writing of 40 cents.

Accuray Signs Long-Term Strategic Development And Supply Agreement With MedPhoton For Volumetric Image Guidance Solutions For The CyberKnife® System

Accuray Signs Long-Term Strategic Development And Supply Agreement With MedPhoton For Volumetric Image Guidance Solutions For The CyberKnife® System

Collaboration Designed to Expand Clinical Versatility of the CyberKnife® System with Addition of medPhoton Novel Imaging Solution

Accuray Hosts Regional AERO Users' Meeting

Accuray Hosts Regional AERO Users' Meeting

Leading Oncology Specialists Discuss Best Practices and Innovations in Cancer Treatment

Accuray (ARAY) Strong On High Relative Volume Today

Accuray (ARAY) Strong On High Relative Volume Today

Trade-Ideas LLC identified Accuray (ARAY) as a strong on high relative volume candidate

MedStar Georgetown University Hospital Treats 1,000 Prostate Cancer Patients With The CyberKnife® System

MedStar Georgetown University Hospital Treats 1,000 Prostate Cancer Patients With The CyberKnife® System

Patients Benefit from Fewer Treatment Sessions and Minimal Side Effects

Commit To Purchase Accuray At $4, Earn 17.7% Annualized Using Options

Commit To Purchase Accuray At $4, Earn 17.7% Annualized Using Options

Investors eyeing a purchase of Accuray Inc stock, but tentative about paying the going market price of $5.03/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the June put at the $4 strike, which has a bid at the time of this writing of 25 cents.

Accuray Announces First Radiation Therapy Systems Installed In Qatar, Latvia And Bulgaria

Accuray Announces First Radiation Therapy Systems Installed In Qatar, Latvia And Bulgaria

Premier Qatar, Latvian Cancer Centers to Offer Patients Treatment with the CyberKnife® System; Leading Bulgarian Hospital to Provide Treatment with the TomoTherapy® System

RSI Alert: Accuray (ARAY) Now Oversold

RSI Alert: Accuray (ARAY) Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.